Lauren Martz

ARTICLE | Emerging Company Profile Oxford spinout is using a 20-year AML biobank to develop TCR engagers against a largely untapped antigen class By Lauren Martz, Executive Director, Biopharma Intelligence Yellowstone is using a platform built around HLA class II-presented antigens to address the target discovery bottleneck in immuno-oncology, identifying cancer-selective targets from a largely untapped antigen source and designing T cell receptor-based therapies against them.

ARTICLE | Regulation FDA approval moves Tryngolza from rare FCS into severe hypertriglyceridemia, giving Ionis its first shot at a broad cardiometabolic market By Lauren Martz, Executive Director, Biopharma Intelligence A highly anticipated label expansion for triglyceride-lowering therapy Tryngolza olezarsen marks a milestone for Ionis as it completes its transition from discovery engine to integrated biopharma.

ARTICLE | Product Development As therapies for one form of retinitis pigmentosa near the market, new technologies put subtype-agnostic therapies in reach By Lauren Martz, Executive Director, Biopharma Intelligence Nearly a decade after Luxturna was expected to open the door for gene therapies across inherited retinal diseases, retinitis pigmentosa is again becoming a proving ground for the field’s most advanced genetic medicine technologies.